A Reusable Trial Network Is Not the Same as a Ready Site

The policy signal is stronger than the legislation alone

The Faster Clinical Trials Act is a proposal, not an enacted operating requirement. Its provisions, funding, and implementation could change. The more useful near-term signal is that federal policy is increasingly treating clinical trial capacity as durable infrastructure rather than something rebuilt for each protocol.

That direction is also visible in the earlier Cures in Care legislative framework. The framework described reusable point-of-care platforms, regional and national pilots, shared training, technical support, interoperability, and implementation pathways for providers outside academic medical centers. (auchincloss.house.gov)

FDA policy already supports several building blocks. Its final guidance on trials with decentralized elements allows appropriately selected activities to occur through telehealth, home visits, local laboratories, and local healthcare professionals. It also makes clear that sponsors and investigators retain responsibility for coordination, supervision, safety, records, and data quality. (fda.gov)

The operational question, therefore, is not whether research can move closer to routine care. It is whether the network can do so repeatedly without recreating its controls every time.

Build a reusable core and a protocol-specific overlay

A functioning network needs a clear boundary between capabilities that can be maintained across studies and requirements that must be assessed for each protocol.

The reusable core should include organizational qualifications, investigator credentials, staff role profiles, standard contract language, privacy and security reviews, system inventories, laboratory certifications, pharmacy capabilities, equipment records, training infrastructure, language capacity, quality procedures, and documented escalation pathways. These elements still require periodic review, but they should not begin from zero for every study.

The protocol-specific overlay includes the actual eligibility criteria, visit schedule, safety profile, investigational product requirements, endpoint assessments, recruitment assumptions, staffing load, equipment needs, local standard of care, and participant support model. A reusable network cannot make these considerations generic.

This distinction matters for feasibility. Sponsors and CROs should be able to retrieve verified baseline capabilities quickly, while sites should still have enough time and protocol detail to evaluate whether the study can be executed safely and predictably. The objective is not to eliminate feasibility. It is to stop asking sites to repeatedly document information that has not changed.

• Maintain a controlled network capability profile with named owners and expiration dates.
• Use protocol-specific feasibility questions only where the answer could materially affect delivery.
• Document capability gaps as activation conditions rather than burying them in email.
• Reconfirm investigator time, coordinator capacity, competing studies, and realistic patient availability for every protocol.

Network membership does not resolve care and research handoffs

Point-of-care and hybrid models introduce more organizations into the participant journey. That can reduce travel, but it also creates more handoffs where information can be delayed, misunderstood, or lost.

FDA’s decentralized-trial guidance distinguishes between routine activities that local healthcare professionals may perform within their normal qualifications and research-specific activities requiring protocol knowledge and appropriately trained trial personnel. The guidance also expects protocols and trial documents to describe where activities occur, who performs them, how adverse events are managed, and how records move back to the investigator. (fda.gov)

The practical tool is a responsibility map built around the participant journey. For every visit and procedure, the team should identify the performer, location, source record, data recipient, review deadline, payment mechanism, escalation route, and backup plan.

This is especially important when an abnormal laboratory value, missed assessment, technology failure, or urgent symptom occurs outside the main research site. “Contact the study team” is not an adequate workflow. Sites need defined response times, after-hours coverage, documentation expectations, and authority for directing the participant to local or emergency care.

• Who confirms eligibility and signs off before randomization?
• Who receives and reviews local laboratory or imaging results?
• Who determines whether an event is reportable, and how quickly must local providers communicate it?
• Who reconciles medication changes made during routine care?
• Who contacts the participant when a remote assessment is incomplete?

Interoperability must be designed around traceability

Connecting an electronic health record to a research platform does not, by itself, create a reliable data workflow. A reusable network needs to know where each critical data element originates, how it is transformed, who reviews it, and which record is authoritative.

FDA recommends that decentralized-trial documentation identify data origin, data flow, remote acquisition methods, service providers, visit locations, and the people generating trial data. The agency also recommends risk-based monitoring that addresses the trial’s decentralized features. (fda.gov)

Operationally, that means testing real scenarios before enrollment. Can a coordinator retrieve a local laboratory report promptly? Are units and reference ranges preserved? Can a correction be traced? Does the investigator see safety-relevant data before it is transferred into the EDC? What happens if a participant completes an electronic outcome assessment but the transmission fails?

Reusable networks should maintain standard data-flow templates, integration validation records, access controls, downtime procedures, and reconciliation reports. Each protocol can then adapt a tested structure instead of inventing a new one.

Community access requires funded capacity, not just additional locations

Community providers can extend access, improve local trust, and reduce participant travel. They should not be treated as free infrastructure.

A 2026 hybrid decentralized oncology implementation study found that workable community models depended on local champions, clear roles, communication pathways, adverse-event procedures, literacy-sensitive materials, and workflows designed to minimize burden on non-research staff. The project also mapped data movement and adapted monitoring plans for hybrid participation. (pubmed.ncbi.nlm.nih.gov)

Those lessons apply beyond oncology. A community clinic may need time for referral review, record retrieval, participant education, scheduling, local procedures, safety communication, invoices, and problem resolution even when it is not operating as a traditional investigator site. Those activities need an owner and a payment pathway.

The Society for Clinical Research Sites has similarly warned that trial modernization can overlook dedicated research sites, shift work without funding it, and exclude site operators from design decisions. (myscrs.org)

In multilingual and geographically dispersed markets, readiness also includes translated and culturally usable materials, staff who can communicate in the participant’s preferred language, dependable courier and specimen plans, and contingencies for weather or infrastructure interruptions. Access is not created by adding a location to a map. It is created by making participation executable there.

Reusable networks need maintenance between protocols

Traditional startup treats readiness as a project phase. A standing network must treat it as an ongoing operating state.

ICH E6(R3), finalized by FDA in September 2025, emphasizes fit-for-purpose quality, clear allocation of activities, qualified personnel, investigator selection, sponsor oversight, and risk-based quality management. Those principles support a network model, but they also make passive network membership difficult to defend. (fda.gov)

A site that enrolled successfully 18 months ago may now have different staff, equipment, referral relationships, system access, or competing studies. Network operators need a routine cadence for refreshing credentials, documenting turnover, reviewing deviations, testing escalation pathways, reassessing vendors, and confirming that promised capacity still exists.

The most useful network metrics will therefore measure readiness and execution, not directory size. Track time from protocol release to credible feasibility, time to contract and budget completion, training completion before initiation, first-participant cycle time, data latency, safety communication timeliness, specimen failures, deviations by workflow, staff turnover, and participant burden indicators.

What sponsors, CROs, and sites can do now

Organizations do not need to wait for legislation to begin building reusable infrastructure. The immediate opportunity is to identify which startup and delivery activities are genuinely repeatable and which remain protocol-dependent.

Sponsors and CROs should involve sites when defining network standards, use verified capability data to reduce repetitive questionnaires, and budget for the coordination work created by distributed models. Sites should maintain current capability records, document capacity constraints honestly, and map the external providers and services they can supervise reliably.

The strongest network will not be the one with the largest list of locations. It will be the one that can accept a protocol, identify its operational risks quickly, assign responsibilities clearly, activate appropriate locations, and maintain participant protection and data reliability across every handoff.

That is the difference between a reusable network and a reusable list of names.

• Create a minimum reusable-readiness dataset for every participating organization.
• Establish a standard participant-journey and responsibility-mapping process.
• Predefine contract, privacy, data-access, and payment pathways for community partners.
• Run tabletop exercises for urgent safety events, missing data, shipment failures, and technology downtime.
• Review network readiness quarterly, not only when a sponsor selects a site.